Eli Lilly (LLY) expects 2014 EPS of $2.77-$2.85 vs consensus of $2.78, with the company's guidance "reflecting the impact of patent expirations."
Forecasts revenue of $19.2-19.8B vs Street estimates of $19.55B.
Sees net income at $3B and operating cash flow of $4B.
Reaffirms commitment to maintain dividend at least at current level.
Late-stage pipeline includes 13 medicines in Phase III development or submission stage.
Eli Lilly's 2013 financial expectations remain unchanged. (PR)